Who
Nimish P. Shah
Director
Company insider
Files Form 4 as: Director, Korsana Biosciences; Director, Apogee Therapeutics; 10% owner, KalVista Pharmaceuticals; 10% owner, Tricida; Director, Instil Bio; 10% owner, Bellerophon Therapeutics.
In numbers
- Trades disclosed
- 54
- Buys
- 16
- Sells
- 0
- Bought
- $41.8M
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 14 Aug 2018
- Last trade
- 9 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 10 Sep 2026 | Korsana Biosciencesoption or derivative | SEC FORM 4 Code A | —48,445 at $0.00 | filing |
| 9 Sep 2026filed 10 Sep 2026 | KRSA Korsana Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,445 at $0.00 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | $236.4M1,750,000 at $135.11 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | $911.1M6,743,321 at $135.11 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —47,758 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | $911.1M6,743,321 at $135.11 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —47,758 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —365,853 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,370 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,461 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,657 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —365,853 | filing |
| 3 Sep 2026filed 3 Sep 2026 | Apogee TherapeuticsBiotechnology | SEC FORM 4 Code D | $236.4M1,750,000 at $135.11 | filing |
| 9 Jun 2026filed 11 Jun 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,657 at $0.00 | filing |
| 10 Oct 2025filed 15 Oct 2025 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $15.0M365,853 at $41.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | Apogee Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,461 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.